a public good project by the
Synthesis
Company
of California

© 2026

Franz Rischard | doi.page

0 works0 citations0 h-index

Franz Rischard

University of Arizona(US)American Society of Addiction Medicine(US)Banner - University Medical Center Tucson(US)

Publications by Year

Research Areas

Pulmonary Hypertension Research and Treatments, Cardiovascular Function and Risk Factors, Congenital Heart Disease Studies, Chronic Obstructive Pulmonary Disease (COPD) Research, Heart Failure Treatment and Management

Most-Cited Works

→ Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity(2020)356 cited
→ Endothelial HIF-2α Contributes to Severe Pulmonary Hypertension by Inducing Endothelial-to-Mesenchymal Transition(2017)178 cited
→ PVDOMICS(2017)160 cited
→ Exercise-Induced Pulmonary Hypertension(2018)92 cited
→ Clinical Characteristics and Transplant-Free Survival Across the Spectrum of Pulmonary Vascular Disease(2022)91 cited
→ Pathogenic role of calcium-sensing receptors in the development and progression of pulmonary hypertension(2016)81 cited

→ Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT(2022)

81 cited

→ Enhancing Insights into Pulmonary Vascular Disease Through a Precision Medicine Approach. A Joint NHLBI–Cardiovascular Medical Research and Education Fund Workshop Report(2017)78 cited

→ Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial(2021)68 cited

→ Transition from parenteral to oral treprostinil in pulmonary arterial hypertension(2016)63 cited